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Asourunderstandingofmolecularmechanismsleadingtovascularformationincreases,vesselmaintenanceincludingstabilization
of new vessels and prevention of vessel regression began to be considered as an active process that requires speciﬁc cellular
signaling. While signaling pathways such as VEGF, FGF, and angiopoietin-Tie2 are important for endothelial cell survival and
junction stabilization, PDGF and TGF-β signaling modify mural cell (vascular smooth muscle cells and pericytes) functions,
thus they fortify vessel integrity. Breakdown of these signaling systems results in pathological hyperpermeability and/or genetic
vascular abnormalities such as vascular malformations, ultimately progressing to hemorrhage and edema. Hence, blood vessel
maintenance is fundamental to controlling vascular homeostasis and tissue functions. This paper discusses signaling pathways
essential for vascular maintenance and clinical conditions caused by deterioration of vessel integrity.
1.Introduction
The vascular system is not only essential for the maintenance
of tissue homeostasis, but also important for managing a
wide variety of physiological processes. Blood vessels are
actively remodeled and reorganized depending on the tissue
oxygen demand, suggesting that the maintenance of blood
vessels is an active process achieved by a speciﬁc biological
program. While the biology leading to new vessel formation
has been extensively investigated in the last couple of decades
[1], the stabilization of the newly formed vessel and the
maintenance of the existing vasculature have not received
signiﬁcant attention. Part of the reason for this under appre-
ciation is the general assumption that blood vessel patency
is maintained as a passive process relying on continuous
blood ﬂow. This idea has been widely accepted as clinical
observations clearly indicate that hemodynamic changes
leading to a decrease or cessation of blood ﬂow results in
vessel regression [2]. There is little doubt that blood ﬂow is
critically important for determining the vessel fate; however,
the recent advance of vascular biology strongly argues for
the autonomous fate control achieved by blood vessels.
Although this is primarily mediated by endothelial cells
which appear to have intrinsic mechanisms to sense envi-
ronmental changes and accordingly remodel blood vessels,
recent studies indicate pivotal contribution made by vascular
mural cells especially pericytes which can stabilize vessels in
part through modulating the endothelial phenotype [3].
The notion of active signaling required to maintain
the vasculature is supported by several lines of evidence:
(1) as angiogenic growth factors can promote new vessel
formation, inhibition of those growth factors in tumor or
tissue has been demonstrated to cause vessel regression
with variable sensitivity [4–6], (2) disruption of endothe-
lial junctions causes endothelial cell apoptosis leading to
disintegration of blood vessels [7, 8], and (3) numerous
mouse knockout studies describe vascular insuﬃciency in
the later stage of development at which initial vascular
development has been completed and blood circulation is
established. These embryos show lethality at E9.5 or later
due to vascular fragility leading to uncontrolled hemorrhage
and edema. The list of the genes that are implicated in the
maintenance of vessel integrity has been provided in the
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similar phenotype is still growing. In these animals, while
blood vessels form initially with normal vasculogenesis and
angiogenesis,themaintenanceofdevelopingoronce-formed
vessels is impaired at the later stage of development. This
observation implies that vessel formation and maintenance
arediﬀerentlyregulatedandequallyimportantforproducing
sustainable tissue perfusion. Furthermore, these studies
collectively demonstrated that many cellular and noncellular
components in the blood vessel coordinately regulate the
maintenanceofvesselintegrityatvaryingdegreesindiﬀerent
vascular beds. These include endothelial cells, pericytes,
smooth muscle cells, ﬁbroblasts, glia cells, inﬂammatory
cells, and the extracellular matrix (ECM) [9].
2. Lessons from Clinical Trials for
Therapeutic Angiogenesis
The discoveries of angiogenic growth factors considerably
advanced our understanding on biology underlying new
vessel formation. This subsequently laid the foundation
for new possibilities in the treatment of ischemic diseases
over the conventional medical management and invasive
procedures such as catheter-based angioplasty and coronary
bypass surgery. The new approach to facilitating the endoge-
nous revascularization process has been termed therapeutic
angiogenesis. The potential impact of therapeutic angiogen-
esis in clinical medicine is signiﬁcant because it will enable
us to achieve tissue perfusion by manipulating intrinsic
blood vessel growth. However, over the past decades, many
attempts to develop biological interventions for therapeutic
angiogenesis have not produced signiﬁcant clinical beneﬁts
despite the initial success in preclinical studies. Double-blind
randomized clinical trials aiming at biological revascular-
ization in patients with ischemic heart diseases have failed
to demonstrate therapeutic eﬃcacy of any single growth
factor delivery [10–12]. These studies led to the conclusions
that (1) administration of a single growth factor triggering
only the initial phase of angiogenesis is not suﬃcient to
drivethewholeangiogenicprocess,(2)vascularmaintenance
is a crucial process to establish functionally meaningful
perfusion, and (3) reevaluation of the detailed biological
mechanism of new vessel formation is imperative for the
successful clinical application.
As currently understood, new vessel formation is trig-
gered by endothelial cell activation and sprouting coor-
dinated with controlled detachment of the surrounding
mural cells, and proteolytic remodeling of the basement
membrane and the extracellular matrix. This initial step
is followed by assembly into a nascent vascular structure,
lumen formation, and, ﬁnally, maturation of the newly
formed endothelial tube and expression of endothelial cell
survival factors. Throughout the process, proangiogenic fac-
tors such as vascular endothelial growth factor (VEGF) and
ﬁbroblast growth factor (FGF) diﬀerentially regulate deﬁned
subpopulations of endothelial cells in the angiogenic sprout,
promoting endothelial migration at specialized tip cells and
proliferation of the stalk cells. Mural cells are then recruited
by platelet-derived growth factor (PDGF) and transforming
growth factor-β1( T G F - β1) to stabilize the nascent blood
vessels. In contrast with the initial phase of vessel sprouting,
endothelial cells stop migration and proliferation in the
maturation step and restore the barrier function of vessels.
It is, therefore, reasonably assumed that to counteract the
action of proangiogenic factors, vessel stabilization requires
activation of distinct cellular signaling pathways diﬀerent
from those that initiate vascular cell mobilization. In fact,
VEGF-A, one of the most potent growth factors that initiates
strongvasculargrowth,isknowntoincreasevascularperme-
ability[13],which,inturn,cancompromisethebarrierfunc-
tion when its action persists. By contrast, other angiogenic
growth factors such as ﬁbroblast growth factor 2 (FGF2) and
angiopoietin 1 (Angpt-1) do not cause vascular hyperper-
meability. While both FGF2 and VEGF-A are potent angio-
genic stimulators, capillaries generated by FGF2 are tightly
sealed and morphologically diﬀerent from VEGF-induced
capillaries which have multiple fenestra and transendothelial
channels [14]. This strongly suggests that VEGF and FGF
induce expression of unique subsets of genes by activating
distinctsignalingprogramsintheangiogenicprocess[15].In
viewofthis,itisconsideredthatunderstandingofthespeciﬁc
role of each growth factor at speciﬁc stages of vascular devel-
opment is important to successfully control the angiogenic
process. Thus, the approach to control vascular stabilization
and maintenance needs to be also considered in the practical
application of therapeutic angiogenesis in the future.
3. Molecular and CellularComponents
Important for VesselMaintenance
3.1. VE-Cadherin-Based Endothelial Junction. Endothelial
intercellular junctions, critically important for the main-
tenance of vascular integrity, are comprised of distinct
adhesion structures including adherens, tight, and gap junc-
tions [16]. Unlike epithelial junctions which are vertically
polarized, endothelial adherens and tight junctions, con-
tributing to the structural maintenance of the endothelium,
are intermingled and do not assume stratiﬁed localization
[17].Interestingly,inendothelialcells,althoughVE-cadherin
can form a complex with polarity proteins such as Par6 and
Par3, this complex lacks atypical-PKC which is required for
polarity formation in epithelial cells [18]. This may explain
nonstratiﬁed endothelial adherens and tight junctions. It
is generally regarded that adherens junctions are primar-
ily important for the control of endothelial permeability
whereas tight junctions are dependent on the formation of
adherentjunctionsandimplicatedinblockingthemovement
of lipids and integral membrane proteins between the apical
and basolateral surfaces of the cell [16, 19].
In endothelial cells, VE-cadherin, a calcium-dependent
adhesion protein mediating transhomophilic interactions,
localizes at cell-cell contacts, regulating the formation of
adherens junctions, and linking the site of the junc-
tion to the actin cytoskeleton. In the quiescent endothe-
lium, VE-cadherin-based junctions are subjected to contin-
uous reorganization, which renders endothelial junctions
highly dynamic and sensitive to extracellular stimuli.International Journal of Vascular Medicine 3
In fact, during the process of new vessel formation, endothe-
lial cells undergo dynamic rearrangement upon angiogenic
stimuli while continuously reorganizing cell-cell junctions
and maintaining barrier function at the same time. This
coordination is largely regulated by adhesion molecules at
intercellular junctions and is particularly important for tube
stabilization and restoration of the full barrier function.
Thus, junction proteins play a critical role in controlling
vascular integrity both in developing and existing vessels.
Among these, VE-cadherin is crucial for this regulation for
its capability to remodel actin cytoskeleton viamodifying the
function of small GTPases [20]. Disruption of VE-cadherin
function in the developing vasculature or the adult vascu-
lature results in severe outcomes manifested by signiﬁcant
defects in the vasculature due to vessel collapse, regression,
and endothelial apoptosis, leading to extensive hemorrhages
[7, 8]. Mouse embryos lacking Cdh5, encoding VE-cadherin,
die at E9.5 due to defects in vessel remodeling [7].
3.2. Pericyte-Endothelial Cell Interaction. Pericytes are mes-
enchymal-derived cells which are positioned around microv-
essels and cover gaps between endothelial cells [3, 21].
Although pericytes and endothelial cells are embedded
within the same basement membrane, they make special
interfaces at peg and socket contacts where the base-
ment membrane is absent and gap and adherens junc-
tion constituents are deposited. Besides forming physical
contacts, the peg-socket contact is thought to facilitate
communication between these two cell types, in which
pericytes and endothelial cells respond to signals generated
by the counterpart [22]. As has been described extensively
in numerous mouse genetic models, failure of pericyte-
endothelial cell communication results in severe and often
lethal vascular defects at the later stage of embryogenesis
exempliﬁed by impaired vascular formation, stabilization,
and remodeling. While in these mice, vascular develop-
ment is initiated by vasculogenesis and angiogenesis, sub-
sequent vessel maturation and stabilization are defective
with reduced pericyte coverage. Pericyte-endothelial cell
interaction is mediated by multiple growth factor systems
including PDGF, TGF-β, sphingosine-1-phosphate, Tie-2,
and Notch, which are required for pericyte diﬀerentia-
tion, recruitment, and expansion. On the other hand,
pericyte coverage promotes vessel maturation by resolving
angiogenic signals and reducing endothelial proliferation.
Alterations in pericyte density or the stable attachment of
pericytes to endothelial cells are associated with human
pathological conditions such as diabetic microangiopathy,
venous malformation, and hereditary stroke and dementia
syndrome CADASIL. Moreover, pericytes of tumor vessels
presentmultipleabnormalities,includinganabnormalshape
and altered gene expression of more immature and less-
contractile markers [23]. These pericytes show loose asso-
ciation with the endothelium and extend cellular processes
into the stroma. Aberrations in pericyte-endothelial cell
communication are attributed to the aggressive nature of
tumor angiogenesis and the high incidence of metastasis
[24]. Signaling systems and pathological conditions related
to pericyte functions are discussed in the following sections.
3.3. Extracellular Matrices and Matrix Metalloproteinases. As
a major structural component of resistant vessels, the ECM
plays a substantial role in the maintenance of vessel integrity.
The ECM of the blood vessel wall exists mainly in three
forms: the interstitial matrix which ﬁlls intercellular spaces
of the media and the adventitia, elastic laminae of artery,
and the basement membrane which is a sheet-like structure
that localizes underneath the endothelium and supports
both endothelial cells and pericytes [25, 26]. Reduction
of the ECM component in the vascular wall predisposes
to compromised vascular structural integrity. For example,
patients with osteogenesis imperfecta and Ehlers-Danlos
syndrome caused by genetic disorders of major ﬁbrillar
collagens such as type I and type III collagen, respectively,
often present aortic aneurysm and its rupture in early
adult life [27]. Aortic aneurysm also occurs as a result
of atherosclerotic changes in which normal architecture of
aorta is progressively destructed by increased activity of
matrixdegrading enzymes,potentially leadingto devastating
rupture as the disease advances [28]. Besides the degenerated
vessel wall, aortic aneurysm features chronic inﬂammation
and a loss of ECM such as medial elastin. Increased matrix
metalloproteinase (MMP) production/activity in the vascu-
lar wall is thought to be responsible for ECM degradation
of this disease. Speciﬁcally MMP-2 and MMP-9 have been
implicated in the pathogenesis of aneurysm due to their
capability to degrade elastin and increased expression levels
in the aneurysm tissue and the plasma of patients [29].
Moreover, the imbalance of MMPs and tissue inhibitors of
MMPs (TIMPs) is believed to promote disease progression.
In the mouse genetic model, whereas either MMP-2 or
MMP-9 deﬁciency is resistant to aneurysm formation [30,
31], disruption of TIMP-1, an MMP-9 inhibitor, leads to
exaggerated aneurysm growth [32]. These results conﬁrmed
the contribution of MMPs to aneurysm formation and
progression through ECM degradation and subsequent
impairment of structural integrity of large vessels.
As ECM degradation by MMPs activates quiescent
endothelial cells and thus triggers angiogenesis, constitutive
endothelial-matrix interaction is thought to maintain vas-
cular homeostasis and thereby prevent angiogenic vascular
growth [33]. Therefore, endothelial attachment to the base-
ment membrane is important for the establishment of stable
and mature blood vessels. Besides the basement membrane,
the adventitial matrix mainly containing ﬁbrillar collagens
and ﬁbronectin produced by ﬁbroblasts also contributes to
the maintenance of vascular integrity not only as structural
scaﬀold, but also as a mediator of vascular remodeling in
response to ﬂow changes or vascular injury [34]. Recent
study revealed the dynamic nature of adventitial ﬁbroblasts
which are capable of modulating vascular functions through
aparacrinemechanism.Fibroblastssecretecytokines,growth
factors, and reactive oxygen species (ROS), actively control-
ling endothelial cell interaction with leukocytes and thus the
inﬂammatory process of the vascular wall.
The importance of the ECM in embryonic vascular
development has also been shown by an observation of mice
lacking histone deacetylase 7 (HDAC7). HDAC7, exclusively
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stage, maintains vascular integrity by repressing MMP-10
expression. HDAC7 null mice show embryonic lethality after
E11.0 due to a failure of endothelial cell adhesion, leading to
vessel dilatation and rupture [35].
3.4. Protein Tyrosine Phosphatase and Reactive Oxygen Species
(ROS). Although physiological levels of ROS, serving as a
signaling mediator in the vascular system, are important
for the maintenance of vascular homeostasis and vascular
integrity, oxidative stress induced by elevated levels of ROS
may contribute to the initiation and development of vascular
dysfunction associated with hypertension and diabetes [36].
The mechanism of action by which ROS cause vascular
dysfunction includes protein oxidation by oxidants such as
peroxynitrate anion (OONO−)a n dH 2O2. These ROS can
increase tyrosine nitration (nY), cysteine (Cys), and zinc
thiolate(ZnS4)oxidation,aﬀectingimportantcardiovascular
proteins such as eNOS, prostacycline synthase, MnSOD, and
sarcoendoplasmic reticulum calcium ATPase (SERCA) [37].
Protein oxidation may also lead to junction instability by
targeting important components of the junction structure.
Increasedvascularpermeability is usuallyreversibleanddoes
not deteriorate vascular integrity because endothelial cells
canquicklyrestore the barrier functionby reestablishing VE-
cadherin-based junctions; however, prolonged permeability-
inducing stimuli may cause a more profound eﬀe c ts u c ha s
accumulationofROS.ROScanirreversiblyinactivateprotein
tyrosine phosphatases (PTPs) by oxidizing a Cys residue in
the catalytic center, thereby aﬀecting the function of PTPs
[38]. Given the importance of VE-PTP and other tyrosine
phosphatases in the stabilization of the VE-cadherin com-
plex, accumulation of ROS in endothelial cells may impair
endothelialbarrierfunctionbyhyperphosphorylationofVE-
cadherin, thus deteriorating vascular homeostasis [39, 40].
4.SignalingSystems That Control
VascularStability
4.1. VEGF Signaling. The VEGF gene family consisting of
VEGF-A, B, C, D, and placenta growth factor (PlGF) in
humans is essential for a wide variety of vascular functions
[41]. Multiple isoforms of VEGF generated by alternative
splicing diﬀer in their ability to bind heparan sulfate, which
determines their bioavailability, and may play distinct roles
invasculardevelopment[42].VEGF-Aisapotentangiogenic
factor originally identiﬁed as a factor capable of increasing
vascular permeability through disruption of endothelial
junctions [43]. Endothelial junction stability is primarily
achieved by VE-cadherin homophilic interactions which
form intercellular adherens junctions. VEGF-A induces
phosphorylation of Y658 and Y731 at the VE-cadherin
cytoplasmic domain via Src activation, disrupting binding
of p120-catenin (p120) and β-catenin, respectively. Dissocia-
tion of catenins especially p120 increases endothelial perme-
ability by dismantling VE-cadherin-based junctions, which
is suﬃcient to maintain endothelial cells in a mesenchymal-
like state with a promigratory phenotype [44, 45]. While
VEGF controls VE-cadherin stability by inducing catenin
uncoupling and VE-cadherin internalization, signaling from
cell-cell junctions can also regulate growth factor signaling
leading to actin reorganization. In fact, VE-cadherin mod-
ulates VEGF-induced Erk1/2 and Akt activation and shear
stress response [46, 47].
Although VEGF-A disrupts endothelial junctions, which
can potentially compromise vascular integrity when the
action is prolonged, VEGF signaling is indispensable for
physiological endothelial functions and vascular homeosta-
sis. Apart from the angiogenic property, VEGF is widely
recognized as a vascular protective factor with its ability
to increase nitric oxide (NO) and prostacyclin (PGI2)
production in endothelial cells [48, 49]. Of these, NO has
been implicated in mediating the eﬀects of VEGF on vasodi-
latation and the maintenance of antiapoptotic signaling
through VEGFR2-induced PI3K activation leading to Akt
andeNOSphosphorylation.Whileendothelium-derivedNO
exerts antioxidant and anti-inﬂammatory properties, NO
produced by both endothelial cells and platelets inhibits
platelet aggregation, thereby playing an antithrombotic role.
NO has pleiotropic antiatherogenic actions by preventing
endothelialdysfunctionandsmoothmusclecellproliferation
which are both required for the initiation and progression
of atherosclerosis. Mice lacking eNOS present impaired
response to vascular injury and ischemia recovery [50].
Endothelial cell activation, critical to triggering an
inﬂammatory response, induces the fusion of Weibel-Palade
bodies containing Von Willebrand factor (vWF), tissue
plasminogenactivator(tPA),P-selectin,IL-8,andendothelin
with the plasma membrane. This process transfers these
molecules to the cell surface where they promote the
recruitment of leukocytes and platelets [51]. NO acts in an
anti-inﬂammatory manner by reducing leukocyte adhesion
on the endothelium through inhibiting exocytosis of Weibel-
Palade bodies. This process is regulated by the activity of
N-ethylmaleimide-sensitive factor (NSF), which is a major
component of the exocytotic traﬃcking machinery [52].
NO appears to inhibit Weibel-Palade body exocytosis from
endothelial cells through inhibiting NSF disassembly activity
by nitrosylating critical cysteine residues of NSF.
Moreover, a recent study demonstrated that autocrine
VEGF signaling is required for endothelial cell survival in a
cell-autonomousmannerundernonpathologicalconditions.
Endothelial-speciﬁc deletion of the VEGF-A gene in mice
leads to progressive endothelial degeneration and sudden
death by 25 weeks of age due to vascular insuﬃciency, sug-
gesting that endogenous VEGF produced by endothelial cells
is crucial for vascular homeostasis [53]. Precise regulation of
diﬀerential VEGF signaling that can promote both endothe-
lialsurvivalandjunctiondisruptionisnotwellunderstoodat
thispoint;however,accumulatingevidencepointsthatVEGF
coreceptor systems are capable of modifying VEGF signaling
outcomes in a context-dependent manner. Several studies
described an essential role of VE-cadherin in VEGF-induced
Akt activation required for endothelial cell survival [7, 54].
VE-cadherin, sensing cellular spatial information depending
on cell density, modulates VEGF signaling by controlling
VEGFR2 endocytosis that is required for Erk1/2 activation
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respond to VEGF stimuli in order to accommodate the
environment and tissue demands.
The family of Roundabout (Robo) transmembrane
receptors is the canonical receptor for the signaling molecule
Slit, regulating commissural axon guidance [56]. Robo4 is an
endothelialcell-speciﬁcmemberoftheRoboreceptorfamily,
which is another signaling system that has the capacity to
modulate VEGF signaling. Robo4 inhibits VEGF-induced
vascular permeability and angiogenesis by binding and
signaling through UNC5B. Thus, Robo4-UNC5B signaling
inendothelialcellsplaysaroleinthemaintenanceofvascular
integrity by antagonizing the action of VEGF [57].
Observations of tumor vasculature provided insightful
information with regard to mechanisms of vessel fragility
and leakiness, which is potentially applicable to anticancer
therapy [58]. VEGF is recognized as a key factor required
for the growth of tumors with its inherent overproduction
in many human malignancies [59]. The tumor microen-
vironment is characterized by hypoxia, low pH, and high
interstitial ﬂuid pressure, all of which underlie exaggerated
production of proangiogenic factors such as VEGF through
HIF1α activation in the tumor milieu. Unregulated VEGF
expression causes vascular hyperpermeability that leads to
leakage of plasma proteins into the stroma, further stimu-
lating persistent angiogenesis and creating a self-reinforcing
vicious cycle [60]. As a result, the abnormal tumor vascula-
ture showing chaotic networks composed of heterogeneous
immature vessels is formed. Structurally, in these tumor
vessels, endothelial cells have wide junctions and multiple
fenestra with loose association with pericytes and the base-
ment membrane, resulting in hemorrhage and edema which
limit eﬃcient perfusion. Therefore, normalization of tumor
vessels using anti-VEGF strategies has emerged as a new
approachtocancertherapy[58,61].VEGFinhibitionprunes
the immature vasculature including excess branches and
enhancespericytecoverage,stabilizingvesselsanddecreasing
tumor vessel permeability. These anti-VEGF eﬀects lead to
improvement of tumor perfusion and oxygenation, resulting
in increased sensitivity to chemotherapeutic agents [62, 63].
4.2. FGF Signaling. FGFs comprise one of the most versatile
and complex signaling families in vertebrates, playing critical
roles in a wide variety of biological processes [64]. FGFs
are broad-spectrum mitogens that stimulate various cellular
functions including migration, proliferation, and diﬀerenti-
ation [65]. FGF2 is recognized as a cell survival factor that
inhibits apoptosis in many cell types including endothelial
cells [66]. The expression pattern of FGFs is very variable,
ranging from nearly ubiquitous (FGF1 and 2) to highly
restricted to particular cell subsets at speciﬁc developmental
stages (FGF3, 4, 8, 17, and 19). In pathological conditions
such as angiogenesis, inﬂammation, and malignancies, FGFs
are abundantly secreted from various cell types including
monocytes, tissue macrophages, endothelial cells, stroma
cells, and tumor cells [65].
Despite the recognition of FGF as a strong in vivo
angiogenic promoter, deciphering its precise functions in the
vascular system has suﬀered from the lack of information
obtained from mouse knockout studies [67, 68]. Disruption
of Fgfr1 or Fgfr2 in mouse embryos results in embryonic
lethality at very early stages of development, precluding
further evaluation of their contribution to vascular develop-
ment [64]. On the other hand, knockout studies of angio-
genic FGF ligands such as FGF1 and FGF2 failed to show
abnormalities in embryonic vascular development, implying
that extensive redundancy exists in the ligand system [69].
One of the diﬃculties investigating the FGF system arises
fromitspromiscuousactionstoavarietyofcelltypesandtis-
sues; however, using tissue-speciﬁc promoters, recent studies
began to uncover roles played by FGFs in the cardiovascular
system. While endothelial FGF signaling is dispensable for
mouse coronary vascular development, myocardial FGF
signaling appears to be essential for triggering hedgehog
activation thatis required for VEGF expression and coronary
vessel formation [70]. Furthermore, analyses of FGF signal-
ing in the adult vasculature revealed signiﬁcant contribution
of FGF to vascular development as well as vascular integrity
maintenance. In the adult mice, basal endothelial FGF
signaling is required for vascular homeostasis. Inhibition of
FGF signaling leads to disassembly of endothelial junctions,
progressing to severe deterioration of vascular integrity [71].
In clear contrast to VEGF which induces disruption of
VE-cadherin-based junctions by Src activation, FGF forti-
ﬁes junction adhesiveness via enhancing coupling of VE-
cadherinwithp120catenin.ThecriticalroleofFGFsignaling
tonewvesselformationisalsodemonstratedinamorerecent
study in which the mechanism of signaling crosstalk between
FGF and VEGF is described. VEGFR2 expression levels are
tightly controlled by endothelial FGF signaling capable of
upregulating VEGFR2 transcription via an Ets-dependent
manner;therebyFGFpromotesneovascularizationindirectly
by regulating endothelial responsiveness to VEGF [72]. It
has been repeatedly shown that while FGF-induced new
vessel formation is often disrupted by VEGF inhibition in
various in vivo angiogenic models, VEGF-induced vascular
formationisnot asmuchaﬀectedbyFGFsignalingdepletion
[67]. Together, these studies suggest the hierarchic control of
newvesselformationbywhichtheFGFsystempromotesnew
vessel growth via controlling VEGF signaling.
4.3. Angiopoietin-1 and Tie2. The angiopoietin- (Angpt-)
Tie2 signaling system has crucial roles in vascular functions
includingangiogenesisandvesselmaintenance[73].Angpt-1
isaligandoftheendothelialcellreceptorTie2,andactivation
of Tie2 signaling enhances endothelial cell barrier integrity
and endothelial-pericyte interaction, thereby promoting
vascular stabilization [74]. While expression of Tie2 is largely
speciﬁc to the endothelium, Angpt-1 production by mural
and perivascular cells facilitates basal Tie2 signaling in quies-
cent endothelial cells that, in turn, is required for endothelial
homeostasis. In contrast, Angpt-2, produced and stored in
Weibel-Paladebodiesinendothelialcells,normallyfunctions
as an Angpt-1 antagonist. Angpt-2 destabilizes the quiescent
vasculature and activates endothelial cells to respond to
angiogenic stimuli. Overexpression of Angpt-2 in the mouse
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thus increases vascular permeability, suggesting that Angpt-
2 inhibits Tie2 signaling and counteract the Angpt-1 action
[75].
Mice lacking Angpt-1 or Tie2 have similar cardiovas-
cular defects, indicating the importance of the Angpt-1-
Tie2 signaling system in cardiovascular development. These
mice die mid gestation (E10.5–E12.5) due to the absence
of hierarchical vascular development and perturbed vas-
cular integrity, manifested by reduced pericyte coverage
and detachment of pericytes from the endothelium [73].
Although Tie2 signaling is thought to be indispensable
for vascular development as previous studies indicated, a
recent study using the tissue-speciﬁc gene deletion strategy
in mice, however, reached the conclusion suggesting that it
may not be the case [76]. Detailed analysis of Angpt-1−/−
embryos showed that the earliest detectable defect seen at
E9.5 is loss of myocardial trabeculations while the vascular
system appears normal. Thereafter, these embryos become
markedly growth retarded with generalized disorganization
of blood vessels. When Angpt-1 is speciﬁcally excised from
cardiomyocytes using the Nkx-2.5 Cre-driver line, the vascu-
lar defects reported in the global knockout are recapitulated,
indicating that vascular phenotypes are dependent on the
cardiacdefectandresultingfromimpairedbloodcirculation.
Moreover, deletion of Angpt-1 in the later stage of vascular
development does not aﬀect pericyte number or vascular
mural cell recruitment. Together, authors concluded that
Angpt-1 is not required for embryonic vascular development
or maintenance of vascular quiescence; however, it functions
as a protective factor, modulating responses to tissue injury
and microvascular abnormality in diabetes [76].
Recent studies began to reveal molecular mechanisms
of Angpt-1 modulating vascular functions. Angpt-1 inhibits
VEGF-induced Src activation through RhoA activation
which leads to Src association with mDia (a RhoA down-
stream target) and sequestration of Src from VEGFR2 [77].
Moreover, Angpt-1 induces translocation of Tie2 to cell-cell
contactsandbridgesTie2proteins,resultingintheformation
of the transdimer of Tie2. Although functional contribution
ofthisTie2homophilicinteractiontojunctionalstabilityand
permeability control is unclear, Angpt-1 preferably transmits
PI3K-Akt signaling in quiescent cells in the presence of
Tie2 transdimers with their close association with eNOS. In
contrast, in isolated endothelial cells, Erk1/2 signaling which
promotes cell migration and proliferation is activated by
Angpt-1 [78, 79].
4.4. Sphingosine-1-Phosphate. Sphingosine-1-phosphate(S1P),
a sphingolipid metabolite found in high concentrations
in platelets and blood, is a lipid mediator that interacts
with GPCRs (S1P1–S1P5) to induce a variety of biological
responses [80, 81]. S1P is an endothelial survival factor
capable of producing NO through Akt activation [82]. It is
also able to enhance endothelial barrier integrity through
S1P1 receptor(Edg1)signalingbypromotingRac1activation
and adherens junction assembly [83]. Administration of the
S1P receptor agonist FTY720 in vivo potently blocks VEGF-
induced vascular permeability, suggesting that S1P receptor
on endothelial cells is able to regulate vascular permeability
[84]. Furthermore, the S1P1 receptor is essential for normal
vascularfunctionsincesystemicantagonismofS1P1 receptor
under basal physiological conditions causes S1P1 receptor
internalization and degradation through receptor phospho-
rylation, leading to enhanced pulmonary vascular leakage
[85, 86].
Genetic studies further indicate the importance of S1P
in the vascular system. S1P1 knockout mice die between
E12.5 and E14.5 due to severe hemorrhage resulting from
a defect in the vascular stabilization process [87]. In mice
in which S1P1 is speciﬁcally deleted from endothelial cells,
the phenotype mimics the one obtained from the embryos
globally deﬁcient in S1P1 whereas vascular smooth muscle
cell-speciﬁc knockout has no eﬀect [88]. While these data
demonstratethatS1P1 signalingintheendotheliumiscritical
fortheregulationofvascularmaturation,thelackofvascular
maturation in these animals is also attributed to impaired
endothelial-pericyte interaction mediated by N-cadherin.
Although structural and functional basis of endothelial-
pericyte interaction has not been well characterized, N-
cadherin is reported to localize at the interface of these
two cell types in the embryonic brain vasculature [89]. This
N-cadherin-based junction mediates pericyte adhesion to
endothelial cells, thereby contributing to vessel maturation
and stabilization [90]. S1P stimulation of endothelial cells
results in activation of Rac1, promoting forward traﬃcking
of N-cadherin to the plasma membrane and the formation
of the N-cadherin-catenin complex [90]. Inhibition of N-
cadherin profoundly attenuates the process of vascular
stabilization in vitro and in vivo, suggesting the speciﬁc con-
tribution of S1P signaling to N-cadherin-induced pericyte
attachment [91].
4.5. PDGF Signaling. The role of platelet-derived growth
factor (PDGF) signaling in the vascular system is established
as an important player to mediate pericyte-endothelial
interaction [92]. PDGFs are major mitogens for mesoderm-
derived cells such as ﬁbroblasts, pericytes, and smooth mus-
cle cells, and for some cell populations of neuroectodermal
origin[93].Inthemouseembryo,perivascularmesenchymal
cells expressing PDGFRβ respond to PDGF-BB (a PDGF-
B homodimer) produced by the angiogenic endothelium.
Paracrine PDGF signaling is thus required for mural cell
recruitment and expansion as has been demonstrated that
PDGF-B expression is particularly abundant in tip cells
of angiogenic vessels and in the endothelium of growing
arteries [94]. The signiﬁcant contribution of PDGF signaling
promotingmuralcellinvestmenttovascularbarrierintegrity
has been shown by mouse genetic studies. Both PDGF-B
and PDGFRβ null mutant mice die perinatally, displaying
lethal hemorrhage and edema caused by a pericyte loss
in microvessels [95]. The results of endothelium-speciﬁc
knockout of PDGF-B further conﬁrmed that PDGF-BB
generated from angiogenic endothelial cells is critically
important for recruitment and proliferation of mural cell
progenitors in vicinity [96]. The absence of pericytes in
capillaries increases their diameters and generates microa-
neurysms by endothelial hyperplasia, suggesting that theInternational Journal of Vascular Medicine 7
pericyte coverage negatively control endothelial cell prolif-
eration. The detailed analysis of PDGFRβ-deﬁcient mice
revealed that vessel instability observed in these mice is
modiﬁed by systemic upregulation of VEGF. The endothelial
junction structure is slightly altered in PDGFRβ-deﬁcient
mice,andthisisattributedtotheVEGFeﬀect,sincetheonset
of endothelial hyperplasia precedes the endothelial junction
abnormality [97].
Itappearsthatinitialinductionofpericytediﬀerentiation
from mesenchymal progenitors is independent of PDGF
signaling and is most likely mediated by other factors
such as TGF-β. Pericyte populations in diﬀerent tissues are
aﬀected in varying degrees by the loss of PDGF signal-
ing in developing PDGFRβ−/− embryos. Therefore, PDGF
signaling is thought to be important in the subsequent
maturation process in the angiogenic vessels where PDGF-
BB released from endothelial cells drives pericyte migration
and expansion [94]. This endothelium-pericyte interplay is
particularly crucial for the formation of the blood-brain bar-
rier (BBB), a speciﬁc physical barrier of the brain capillaries.
Usingpericyte-deﬁcientmousemutantswhichhavedefective
PDGFsignalingintheembryonicoradultvasculature,recent
studies clearly showed that pericytes are necessary for the
formation of the BBB, and that absolute pericyte coverage
determines the extent of vascular permeability. Interestingly,
in the central nervous system vasculature, the formation
of tight junctions and endothelial vesicle transport by
transcytosis are the critical regulator of vascularpermeability
which is increased by pericyte deﬁciency [98, 99].
4.6. TGF-β Signaling. TGF-β family includes TGF-βs, activ-
ins, inhibins, nodal, bone morphogenetic proteins (BMP),
and growth diﬀerentiation factors (GDF), comprising one
of the largest growth factor/cytokine families in vertebrates.
Although TGF-β family members are known to play crucial
rolesinthevasculardevelopment,theirpreciseroleespecially
in endothelial functions is still controversial [100]. This is
probably attributable to the remarkable diversity of their
actions and complex regulation of the signaling system. In
fact, TGF-β eﬀects are highly context-dependent with in
vitro observations suggesting that TGF-β is stimulatory to
endothelial cell functions at low concentrations whereas it
canbeinhibitoryathighconcentrations[100].Moreover,the
presence of pericytes in the endothelial cell culture leads to
TGF-β activation, which, in turn, inhibits endothelial pro-
liferation and migration through VEGFR2 downregulation
[101, 102]. Therefore, one of the important roles of TGF-
β signaling in mural cells is to attenuate the endothelial
cell response to angiogenic stimuli, thereby limiting vessel
overgrowth and resolving the active angiogenic process. This
appears to form a negative feedback loop by which endothe-
lial cells promotes pericyte diﬀerentiation and expansion
that lead to vessel stabilization and, consequently, vessel
maturation.
Genetic studies in mice have indicated the essential role
of TGF-β in pericyte functions and vascular development.
Disruption of the TGF-β1g e n ei nm i c el e a d st oe x t r a e m b r y -
onic vascular defects exempliﬁed by the failure of endothelial
diﬀerentiation accompanied with fragile yolk sac vasculature
[103]. Inactivation of Tgfbr2 in the smooth muscle cell lin-
eage results in vascular defects in the yolk sac and embryonic
lethality between E12.5 and E16.5, suggesting impairment
o fm u r a lc e l lr e c r u i t m e n t[ 104]. The importance of TGF-β
signaling in mural cell function is further endorsed by the
observation that mice with neural crest-speciﬁc deletion of
Tgfbr2 develop a phenotype similar to that of DiGeorge syn-
drome due to the failure of neural crest derivative diﬀeren-
tiation into smooth muscle cells in the cardiac outﬂow tract
[105]. Moreover, mouse phenotypes resulting from targeted
disruption of TGF-βRII, endoglin or activin receptor-like
kinase 1(ALK1) are highly reminiscent of TGF-β1n u l lm i c e ,
showing vascular abnormalities characterized by systemic
vascular dysplasia and recurrent hemorrhage caused by
telangiectasesandarteriovenousmalformations[100].These
studies collectively demonstrate the importance of TGF
family genes in the various aspects of vascular development.
4.7. Notch Signaling. The Notch signaling pathway is an
evolutionarily conserved, intercellular signaling system that
plays important roles in a wide variety of biological pro-
cesses. During vascular development, Notch signaling plays
essential roles in endothelial cell speciﬁcation including
angioblast speciﬁcation, arteriovenous diﬀerentiation, and
tip/stalk cell formation [106, 107]. The critical contribution
of Notch signaling to the endothelium and new vessel for-
mation has been well characterized in mouse and zebraﬁsh
studies. Genetic ablation of Notch1 or a Notch ligand,
Delta-like ligand 4 (Dll4) causes vascular deformation and
embryonic lethality due to defective arterial and venous
speciﬁcation of endothelial cells [108, 109]. In this process,
Notch is a downstream of VEGF signaling, inducing arterial
diﬀerentiation through activation of PLCγ, MAPK, and
EphrinB2/EphB4 signaling. EphrinB2, which is an arterial
endothelial marker, is a direct transcriptional target of Notch
signaling [110]. As signaling components of the Notch
pathwayarecriticallyinvolvedinarteriovenousspeciﬁcation,
deregulation of Notch signaling causes aberrant direct
communication between an artery and a vein, leading to
arteriovenous malformation (AVM). In mouse and zebraﬁsh
genetic models, both loss and gain of function mutations can
result in the formation of arteriovenous malformation and
embryonic vascular remodeling defects [106].
When Dll4 binds Notch1, the intracellular domain of
Notch1 (NICD) is cleaved by γ-secretase and translocates
to the nucleus where it regulates gene transcription. In the
vascularsproutoftheretina,whiletheVEGF-Agradientgen-
erated by astrocytes in the ischemic area induces endothelial
cells at the leading edge to adopt a tip cell phenotype, Dll4
prominentlyexpressedinthetipcellsignalstofollowingstalk
cells through Notch1 to downregulate VEGFR2 and inhibit
ﬁlopodia formation [111, 112]. Thus, during vascular pat-
terning,Notchsignalingisrequiredforstalkcellspeciﬁcation
by actively suppressing the tip cell phenotype, controlling
the number of tip cells and vascular sprouts. In fact, ectopic
activation of Notch signaling in the mouse retina reduces tip
cell ﬁlopodia and the vascular density [113].
Notch signaling appears to be required for vessel sta-
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Notch signaling inhibits endothelial cell proliferation and
motility, thus preventing excessive vessel sprouting and
stabilizing newly formed vessels. Although increased Notch
signaling does not necessarily induce vessel instability, recent
study revealed that coordination of Notch and Wnt signaling
plays a role in stabilization of nascent vessels. Notch-
regulated ankyrin repeat protein (Nrarp), directly induced
by Notch signaling, promotes canonical Wnt signaling and
controls the stability of newly formed vessel anastomosis
[114]. Notch signaling in vascular smooth muscle cells
also contributes to arterial speciﬁcation/diﬀerentiation and
thus to vessel stabilization. Genetic disruption of Notch3,
expressed in smooth muscle cells of arteries, leads to
arterial defects including enlargement of arteries with thin
smooth muscle layers [115]. Interestingly, endothelium-
speciﬁcknockoutofJagged1causesdefectsinsmoothmuscle
cell diﬀerentiation, whereas endothelial Notch signaling and
arteriovenous diﬀerentiation occur normally. This suggests
that endothelial-mural cell crosstalk mediated by Notch
signaling is necessary for proper arterial development.
Endothelial Jagged1 promotes the development of neighbor-
ing vascular smooth muscle through Notch3 activation, and
the loss of Jagged1 in the endothelium causes a deﬁciency
of smooth muscle cell recruitment and diﬀerentiation, thus
leading to vascular instability [116, 117].
5. ClinicalManifestations of Impaired
Vessel Maintenance
The semipermeable compartmentalization achieved by
blood vessels especially by the endothelium is critically
important for normal organ functions and tissue homeosta-
sis [118]. The proximal disorders resulting from the break-
down of the barrier function are bleeding and tissue edema.
The impairment of the barrier integrity can result from
prolonged stimuli of permeability-inducing agents such as
VEGF or genetic abnormalities that lead to fragile vessels
causing by unstable endothelial junctions, impaired vessel
speciﬁcation/stratiﬁcation, and pericyte insuﬃciency. These
congenital vascular abnormalities are collectively referred to
as vascular malformation which includes several diﬀerent
typesaccordingtothetypeofthebloodvesselpredominantly
aﬀected. Among them, venous malformations are the most
common form. Impaired vessel speciﬁcation leads to an
aberrant direct communication of an artery and a vein,
which is termed as arteriovenous malformation (AVM). The
majority of vascular malformations is sporadic and has
no genetic components; however, recent studies identiﬁed
a variety of genetic abnormalities which provide clues to
pathogenesis of vessel abnormalities and mechanisms of
vascular maintenance [119–122].
5.1. Cutaneomucosal Venous Malformations. Venous malfor-
mations, the most common type of vascular malformation,
comprise either superﬁcial or deep veins that are abnormally
formed and dilated in the skin, mucous membrane, or
in any organ system characterized by lesions composed of
enlarged, tortuous venous channels [121]. Although venous
malformations are usually present at birth, due to the slow
nature of disease progression, they may not be diagnosed
at young ages. Genetic abnormalities contribute only 2%
of reported venous malformations; however, recent studies
revealed mutations in the TEK gene, encoding Tie2, in the
familieswithdominantinheritanceofvenousmalformations
[123]. The mutations identiﬁed thus far have been located
at the cytoplasmic domain of Tie2, resulting in ligand-
independent phosphorylation and activation of the receptor.
These autosomal-dominant venous malformations, termed
venous malformations, multiple cutaneous, and mucosal
(VMCM), tend to involve small multifocal, bluish muco-
cutaneous lesions. In addition to the inherited form of
VMCM,somaticmutationscausinglossoffunctionofTie2is
suggested to have a role in the etiology of solitary or multiple
sporadic venous malformations, which are the more com-
mon form of the disease [124].
5.2. Hereditary Hemorrhagic Telangiectasia (HHT). Hered-
itary hemorrhagic telangiectasia (HHT), also known as
Osler-Weber-Rendu syndrome, is a genetic disorder that is
inherited as an autosomal dominant trait and aﬀects 1-2 in
10,000 individuals [120, 125]. HHT causes abnormal blood
vessel formation in the skin, mucous membranes, and often
in organs such as the gastrointestinal tract, lungs, liver, and
brain [120]. The lesions are characterized by mucocutaneous
telangiectases, and in some cases, life-threatening visceral
arteriovenous malformations. Recent genetic studies iden-
tiﬁed responsible genes associated with HHT, all of which
are components of TGF-β family signaling pathways. HHT
type I results from mutations in ENG, coding for endoglin,
ac o r e c e p t o ro fT G F - β receptors. HHT type II causes by
mutationsinACVRL1whichencodesALK1,atypeIreceptor
fortheTGF-β superfamilyligands.Whilemutations ofeither
of the two genes account for most clinical cases, a small
subset of patients carry mutations in MADH4 encoding
Smad4, a transcription factor that mediates TGF-β signaling.
Mouse phenotypes resulting from targeted disruption of
components of TGF-β signaling pathway such as TGF-β1,
TGF-βRII, endoglin, or ALK1 are all leading to severe vascu-
lar abnormality and embryonic lethality at mid gestation, in
some part recapitulating HHT phenotypes [100].
Detailed analysis of HHT gene functions using mouse
models of tissue-speciﬁc or haploinsuﬃcient gene inac-
tivation has begun to reveal the mechanism of HHT
development [120, 126]. Current understanding of HHT
pathogenesis indicates that HHT results from endoglin or
ALK-1 haploinsuﬃciency, where the remaining wild-type
allele is unable to express suﬃcient protein for normal
function. HHT mutations are thought to modify predom-
inantly endothelial cell responses to TGF family ligands
mediated by endoglin and Alk1 since they are relatively
endothelial speciﬁc genes. However, because the vast major-
ity of blood vessels in HHT patients appear to develop and
function normally, perturbation of a pathological process
that requires ﬁnely-tuned TGF-β signaling such as wound
healing and angiogenesis might play as an extra trigger.
While endothelial ALK1 is essential for the establishment
of proper arteriovenous (AV) connections during vascular
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AVM forms following activation of the quiescent endothe-
lium by wound that elicits angiogenesis [127]. In HHT,
the augmented angiogenic response including excessive
endothelial proliferation and exaggerated vessel sprouting is
partially attributable to impaired recruitment of mural cells
to the newly formed vessel due to reduced endothelial cell
secretion of TGF-β1 or reduced TGF-β1-induced responses.
In HHT type I patients, circulating levels of TGF-β1a r e
reduced [128]. Moreover, paracrine TGF-β signaling is
defective in mice with endothelial-speciﬁc deletion of TGF-
βRII or ALK5 as evidenced by reduced phosphorylation of
Smad2 in the adjacent mesothelial cell layer of the yolk sac.
Phosphorylation of Smad2 and diﬀerentiation of smooth
muscle cells can be rescued by exogenous TGF-β1 in the yolk
sac culture, consistent with the idea that lower levels of TGF-
β or reduced responsiveness required for receptor activation
play a role in HHT pathogenesis [129].
In this regard, the recent discovery of thalidomide as a
potential therapeutic agent for HHT conﬁrmed the impor-
tance of mural cell dysfunction responsible for the formation
of fragile vessels. In mice heterozygous for a null mutation
in the endoglin gene, thalidomide treatment stimulates
mural cell recruitment by increasing PDGF-B expression in
endothelial cells and thus rescues vessel defects [130].
5.3. Cerebral Cavernous Malformations (CCMs). Cerebral
cavernous malformations (CCMs) are sporadic or inherited
vascular malformations in the central nervous system
characterized by dilated, thin-walled capillary-like channels
without intervening brain parenchyma. They are one of the
commonest vascular malformations in the brain, aﬀecting
roughly 0.1–0.5% of the general population [131]. Genetic
studies have identiﬁed autosomal dominant mutations
associated with CCMs: KRIT1 (CCM1), CCM2 (MGC4607,
Malcavernin, OSM), and PDCD10 (CCM3) [132]. Although
neitheroftheseCCMproteinsarestructurallyrelatedtoeach
other nor have been implicated as angiogenesis inducers,
recent studies indicated possible mechanisms leading to vas-
cular malformation. KRIT1, originally identiﬁed as a Rap1a
interacting protein, is partially localized at cell-cell contacts
and the loss of KRIT1 accounts for the unstable endothelial
junctions. It has been shown that CCM proteins exist as a
large protein complex, and a defect of one protein can aﬀect
the function of other CCM proteins [133]. KRIT1 or CCM2
is capable of inhibiting RhoA and ROCK which can disas-
semble endothelial junctions and cause hemorrhage [134].
Since Rap1 is able to enhance junction stability and KRIT1
is a Rap1 eﬀector, there is a possibility that the loss of KRIT1
directly aﬀects endothelial junctions in a Rap1-dependent
manner. Rap1 regulates the junctional localization of KRIT1,
which is required for Rap1-mediated endothelial junction
stabilization [135].
Recent mouse genetic studies advanced our understand-
ing of pathogenesis leading to CCM. Disruption of heart
of glass (HEG1), a transmembrane receptor previously
implicatedinCCMfunctionsinzebraﬁsh,resultsindefective
integrity of the heart and the vasculature in mice. HEG1
coupled with CCM proteins through KRIT1 is required for
vascular development and endothelial junction formation
[136]. Haploinsuﬃciency of Ccm2 in mice, a genotype
equivalent to that in human CCM, results in impaired
endothelial barrier function. Interestingly, loss of CCM2
leads to activation of RhoA, and the impaired barrier
function in heterozygous mice is restored by simvastatin, a
drug known to inhibit Rho GTPases [137]. Moreover mice
with global or endothelial cell-speciﬁc inactivation of Ccm3
show defects in embryonic angiogenesis and die at an early
embryonic stage. In response to VEGF stimulation, CCM3 is
recruited to and stabilizes VEGFR2, thereby playing a pivotal
role in VEGFR2 signaling [138].
5.4. Capillary Malformation-Arteriovenous Malformation
(CM-AVM). Capillary malformation-arteriovenous malfor-
mation (CM-AVM) is a recently discovered hereditary
disorder characterized with atypical cutaneous multifocal
capillary malformations often in association with high-
ﬂow lesions such as arteriovenous malformations of the
cerebrospinal and visceral organs or arteriovenous ﬁstulas.
Genetic studies identiﬁed loss of function mutations in
RASA1, which encodes p120-RasGAP [121, 139]. As GTPase
activity leads to, by hydrolysis of GTP to GDP, inactivation
of small GTPases, loss of p120-RasGAP function suggests
the possibility to increased Ras and downstream MAPK
activation. Furthermore, p120-RasGAP has been shown to
interact with p190-RhoGAP, which inhibits RhoA through
a p120 catenin-dependent mechanism and is required for
adherens junction formation [140, 141].
5.5. Cerebral Autosomal-Dominant Arteriopathy with Subcor-
tical Infarcts and Leucoencephalopathy (CADASIL). The clin-
ical relevance of Delta-Notch signaling is manifested by the
cerebral small vessel disease: cerebral autosomal-dominant
arteriopathywithsubcorticalinfarctsandleukoencephalopa-
thy (CADASIL), now recognized as the most common cause
of inherited stroke and vascular cognitive impairment in
adults [106, 142]. CADASIL is inherited as an autosomal
dominanttrait,resultingfrommutationsinNOTCH3,which
causes degeneration of smooth muscle cells of cerebral small
vessels and accumulation of the Notch extracellular domain
(NECD)atthesurfaceofresidualsmoothmusclecells.These
changes lead to thickening of the vessel wall and a reduction
of cerebral blood ﬂow [142, 143]. Genetic studies revealed
that among 33 exons, all CADASIL mutations occur in exon
2–24 of the Notch3 gene within 34 EGF-like repeats, leading
to an odd number of cysteine residues [142].
Genetic disruption of Notch3 in mice causes structural
defects of small arteries because of impaired diﬀerentiation
and maturation of arterial smooth-muscle cells; however,
total loss of Notch3 does not cause CADASIL pathology
[115]. Furthermore, CADASIL-causing mutations of Notch3
can activate RBP-Jκ transcription comparable to wild-type
levels and do not seem to aﬀect Notch signaling per se [144,
145]. Therefore, although the precise cause of the disease is
stillunclear,recentstudiessuggestthatgainofnovelfunction
of the mutant protein, possibly arising from novel protein-
protein interactions rather than defective Notch3 function,
is a likely mechanism for the CADASIL pathogenesis.10 International Journal of Vascular Medicine
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Figure 1: Signaling pathways controlling vascular maintenance. While VEGF signaling disrupts VE-cadherin-based junctions through Src-
mediated VE-cadherin phosphorylation and internalization, FGF signaling promotes p120 association with VE-cadherin, thus increasing
VE-cadherin stability at adherens junctions. Angpt-1 binding to Tie2 at cell-cell contacts leads to formation of Tie2 transdimers which
activates Akt and promotes cell survival. S1P binding to S1P1 (Edg1) is able to stabilize endothelial junctions via Rac1 and promotes
N-cadherin forward traﬃcking required for endothelial-pericyte interaction. HEG1-CCM signaling at endothelial junctions enhances
junctional stability through Krit1 interaction with β-catenin in the VE-cadherin complex. PDGF-BB secreted from endothelial cells
recruit pericytes expressing PDGFRβ.T G F - β produced in endothelial cells induces mural cell diﬀerentiation. TGFβRII is also expressed
in endothelial cells and controls various endothelial functions.
As discussed earlier, Notch pathway is important for
arteriovenous diﬀerentiation and vessel patterning during
embryonic vascular development, and deﬁciency of Notch
signaling can cause arteriovenous malformations [146, 147].
Expression of constitutively active Notch4 (int3) in the
mouse endothelium develops features of brain arteriove-
nous malformations characterized by cerebral arteriovenous
shunting and vessel enlargement [148, 149]. Conditional
activation of the Notch1 gene in endothelial cells of mouse
embryos also causes defects in vascular remodeling progress-
ing to arteriovenous malformations [150]. Analysis of brain
arteriovenous malformations revealed that Notch1 signaling
is upregulated in smooth muscle and endothelial cells of the
lesions surgically resected from human patients [151].
6. Conclusion andPerspective
Regulation of the vascular barrier function is crucial for
tissuehomeostasis.Recently,ourunderstandingofmolecular
mechanisms leading to vessel stabilization has signiﬁcantly
expanded owing to the advance of basic research followed
by critical appraisal of therapeutic angiogenesis trials. It
has also become apparent that the maintenance of existing
vesselsrequiresactivecellularsignalingwhichsharecommon
features with signaling mechanisms involved in the vessel
maturation process of new vessel formation. The signaling
systems controlling vascular maintenance is summarized in
Figure 1. Components of signaling pathways involved in vas-
cular stability often cause vascular malformations as disease
genes. Conversely, genes identiﬁed through genetic studies
of vascular diseases most likely play a role in physiological
regulation of vascular integrity. As has been discussed, vessel
maintenance is successfully achieved by orchestrated actions
ofgrowthfactorsandcytokinesthatarecapableofmodifying
the function of vascular cells especially endothelial cells and
mural cells. Although indispensability of these cell types and
signaling pathways required for the maintenance of vessel
integrity have been unequivocally demonstrated by numer-
ous studies, it is important to further elucidate detailed
molecular mechanisms of signaling interactions between
diﬀerent cell types in the vasculature. The endothelial-
pericyte junctions are anatomically identiﬁed; however,
signals exchanged during new vessel formation and vessel
maintenance between these cells are not clearly understood.
Besides genetic components leading of vascular instability,
epigenetic factors are also playing an important role in
modifying disease manifestations such as the location and
the severity of the vascular abnormality in the presence ofInternational Journal of Vascular Medicine 11
ubiquitous, germline mutations. Further investigationss ex-
ploring this aspect including the “two-hit” mechanism for
disease development and presentation should provide sig-
niﬁcant insights into our understanding to vascular mainte-
nance.
As regulation of vessel maintenance is a fundamental
vascular function associated with a wide variety of vascular
disorders and disease conditions, elucidating the precise
mechanisms will beneﬁt the development of new approaches
for therapeutic angiogenesis and vascular malformations as
well as cancer treatment.
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